Alzheimer'S Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Alzheimer's disease (AD) is the most common cause of dementia, characterized by progressive cognitive decline, memory loss, and behavioral changes. It is a neurodegenerative disorder that primarily affects older adults, with prevalence doubling every 5 years after age 65. Approximately 6.5 million Americans aged 65 and older live with AD, making it a major public health challenge worldwide.
- Amyloid-beta plaques: Extracellular deposits of Aβ peptides (Aβ40, Aβ42)
- Neurofibrillary tangles: Intracellular tau protein aggregates (paired helical filaments)
- Neuronal loss: Progressive death of synapses and neurons, particularly in hippocampus and cortex
- Neuroinflammation: Chronic activation of microglia and astrocytes
- Synaptic dysfunction: Early loss of synaptic markers and function
The amyloid cascade hypothesis proposes that Aβ accumulation is the primary driver of AD pathogenesis:
- Amyloid precursor protein (APP) processing produces Aβ peptides via β- and γ-secretases
- Aβ oligomerization and plaque formation (soluble oligomers are more toxic than plaques)
- Synaptic dysfunction and neuronal toxicity through multiple mechanisms
- Neurofibrillary tangle formation secondary to neuronal stress
- Progressive neurodegeneration and cognitive decline
- Hyperphosphorylated tau (p-tau) forms neurofibrillary tangles
- Tau spreads along neural circuits in a predictable pattern
- Braak staging: I-VI based on tangle distribution
- Tau PET imaging allows visualization of tangle burden
- Cerebral amyloid angiopathy (CAA): Aβ in blood vessel walls
- Granulovacuolar degeneration
- Senile plaques with neuritic cores
- Oxidative stress and mitochondrial dysfunction
- APP (Chromosome 21): Swedish mutation (KM670/671NL), London mutation (V717I)
- PSEN1 (Chromosome 14): Over 200 mutations identified, most common cause of familial AD
- PSEN2 (Chromosome 1): Less common than PSEN1, later onset
- APOE: ε4 allele increases risk (3-4x for heterozygotes, 10-15x for homozygotes); ε2 is protective
- TREM2: R47H variant increases risk ~3x (microglial function)
- CLU: Clusterin variant modestly increases risk
- PICALM: Involved in endocytosis
- BIN1: Bridging integrator 1, tau pathology
- APP A673T: Reduces amyloid processing, protects against cognitive decline
- APOE ε2: Associated with longevity and reduced AD risk
- Age (greatest risk factor - doubles every 5 years after 65)
- Family history (2-4x increased risk with first-degree relative)
- Genetic predisposition (APOE ε4, mentioned above)
- Female sex (higher prevalence, possibly due to longevity)
- Down syndrome (trisomy 21 - extra APP copy)
- Cardiovascular health (hypertension, diabetes, hypercholesterolemia)
- Physical activity (regular exercise reduces risk 28-45%)
- Cognitive reserve (education, mental stimulation)
- Social engagement (maintains brain connectivity)
- Sleep quality (glymphatic clearance of Aβ)
- Traumatic brain injury (repetitive concussions increase risk)
- Smoking (increases risk 1.5-2x)
- Moderate alcohol consumption (may be protective)
- Diet (Mediterranean or MIND diet)
- Memory loss (especially episodic memory - recent events)
- Word-finding difficulties (anomia)
- Disorientation to time and place
- Impaired judgment and decision-making
- Executive dysfunction (planning, organization)
- Visuospatial difficulties (getting lost)
- Agnosia (failure to recognize objects)
¶ Behavioral and Psychological Symptoms
- Apathy (most common)
- Depression and anxiety
- Agitation and aggression
- Sleep disturbances (sundowning)
- Psychosis (delusions, hallucinations)
- Disinhibition
- Eating disturbances
- Preclinical: Biomarker changes, no symptoms
- MCI due to AD: Mild cognitive changes, preserved daily function
- Mild AD: Difficulty with complex tasks, mood changes
- Moderate AD: Needs assistance, behavioral changes
- Severe AD: Loss of verbal ability, mobility decline
- Comprehensive neuropsychological testing
- Mini-Mental State Examination (MMSE): 30-point scale
- Clinical Dementia Rating (CDR): 0-3 scale
- Montreal Cognitive Assessment (MoCA): Sensitive to MCI
- Reduced Aβ42 (reflects plaque formation)
- Elevated total tau (t-tau)
- Elevated phosphorylated tau (p-tau)
- Neurofilament light chain (NfL) - neuronal damage
- Neurofilament light chain (NfL)
- Phosphorylated tau (p-tau181, p-tau217)
- Glial fibrillary acidic protein (GFAP)
- Aβ42/40 ratio
- MRI: Hippocampal atrophy, cortical thinning
- PET amyloid: Florbetapir, florbetaben
- PET tau: Flortaucipir
- FDG-PET: Hypometabolism in posterior cingulate
- Braak stage for tau
- Thal phase for amyloid
- CERAD plaque score
- ABC score for AD neuropathologic change
- Donepezil (Aricept): Mild to moderate AD
- Rivastigmine (Exelon): Mild to moderate AD
- Galantamine (Razadyne): Mild to moderate AD
- Memantine (Namenda): Moderate to severe AD
- Aducanumab (Aduhelm): Anti-Aβ monoclonal antibody, removes amyloid plaques
- Lecanemab (Leqembi): Anti-Aβ protofibrils, slower cognitive decline
- Donanemab (Kisunla): Anti-Aβ plaque, removes tau pathology
- Behavioral interventions
- Sleep hygiene
- Caregiver support
- Occupational therapy
- Anti-tau antibodies
- BACE inhibitors (failed due to side effects)
- Immunotherapies targeting different Aβ epitopes
- Gene therapy approaches
- Neuroprotective agents
- Multiple anti-amyloid immunotherapies
- Anti-tau therapies (LMTM,gosuranemab)
- Neuroprotection studies
- Biomarker-driven trials
- Late-stage intervention may be too late
- Biomarker enrollment criteria
- Heterogeneity of AD
- Comorbidities in elderly populations
- Amyloid-tau interaction hypothesis
- Synaptic plasticity dysfunction
- Microglial biology (TREM2, DAM)
- Network dysfunction
- Resilience and cognitive reserve
- Blood-based diagnostics
- Digital biomarkers
- Multi-modal biomarker panels
- Precision medicine approaches
- DIAN-TU: Familial AD prevention
- A4: Preclinical AD prevention
- FINGER: Lifestyle intervention
- Average survival: 4-8 years after diagnosis (up to 20 years)
- Progression rate varies
- Leading cause of death: 6th in US
- Quality of life impact for patients and caregivers
The study of Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Jack CR Jr, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018.
- Scheltens P, et al. Alzheimer's disease. Lancet. 2021.
- Masters CL, et al. Alzheimer's disease. Nature Reviews Disease Primers. 2025.
- van der Kant R, et al. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience. 2020.
- Sims JR, et al. Donanemab in early Alzheimer's disease. JAMA. 2023.
- Cullen NC, et al. Blood biomarkers for Alzheimer's disease. Molecular Psychiatry. 2024.